One in three American adults will experience an anxiety disorder at some stage in their lives, according to the National Institute of Mental Health, a condition that can severely impact an individual’s capacity to work, manage relationships and perform daily tasks. To tackle anxiety disorders, TruBrain, a cognitive healthcare startup which has generated lifetime sales of $20m, has recently launched a wearable device that uses FDA-cleared micro-electric currents applied to specific areas of the brain to promote calm and blood flow. Designed by industry experts, TruBrain’s device uses neurostimulation backed by thousands of scientific studies and decades of research, with effects becoming apparent in as little as 30 minutes.
The success of the innovative device has made TruBrain among the largest campaigns by amount raised in StartEngine, a leading startup investing platform. Moreover, the cognitive healthcare brand owes a portion of its success to its science-backed personalized drinks package popular among consumers. TruBrain CEO, Chris Thompson notes that their mission is “to empower people to do their best thinking” by alleviating stress and anxiety, improving sleep and encouraging focus and relaxation. The startup’s release of the innovative device represents a significant advance in cognitive healthcare, with the company on track to become a leading cognitive healthcare brand, empowering people to live their best lives.
Notably, the breakthrough comes amid growing interest from backers and investors in the brain tech industry. For example, Neuralink, a neural engineering firm backed by Elon Musk, has acquired FDA approval to test its implants in real-world scenarios and has amassed significant investments to apply it. Likewise, Amazon’s Jeff Bezos and Microsoft’s Bill Gates have funded Neuralink competitor, Synchron.
To keep up with the latest startup news and developments, subscribe to Benzinga’s Startup Investing & Equity Crowdfunding Newsletter.
